Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 3/20 | 0.74 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.74 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.74 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.74 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.74 |
| ▸ | CYP4B1 | P13584 | 2/20 | 0.74 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.74 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.74 |
| ▸ | CYP2A7 | P20853 | 2/20 | 0.74 |
| ▸ | CYP3A7 | P24462 | 2/20 | 0.74 |
| ▸ | CYP2F1 | P24903 | 2/20 | 0.74 |
| ▸ | CYP2C18 | P33260 | 2/20 | 0.74 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.74 |
| ▸ | CYP2J2 | P51589 | 2/20 | 0.74 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.74 |
| ▸ | CYP4F8 | P98187 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8987283 | 0.95 | CYP1A1 (0.74) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL26498639 | 0.91 | CYP1A1 (0.83) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL26498734 | 0.91 | CYP1A1 (0.83) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL26498789 | 0.91 | CYP1A1 (0.83) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL7241617 | 0.87 | CYP1A1 (0.57) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL29698794 | 0.87 | CYP1A1 (0.57) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL23743214 | 0.85 | CYP1A1 (1.00) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL2545199 | 0.85 | ABCB1 (0.62) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL3053111 | 0.85 | CYP3A4 (0.55) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL9293295 | 0.85 | CYP1A1 (0.55) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101068773-A | Melanin concentrating hormone antagonists | PROCTER & GAMBLE (US) | 2007-11-07 | — | — | CN | claimed |
| EP-1667958-A2 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2006-06-14 | — | — | EP | claimed |
| US-6890930-B1 | Quinazolinones | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2005-05-10 | — | — | US | claimed |
| WO-2005033063-A2 | MELANIN CONCENTRATING HORMONE ANTAGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2005-04-14 | — | — | WO | claimed |
| US-20050075324-A1 | Melanin concentrating hormone antagonists | THE PROCTER & GAMBLE COMPANY (US) | 2005-04-07 | — | — | US | claimed |
| US-12365655-B2 | Compounds | CTXT PTY LTD (AU) | 2025-07-22 | — | — | US | disclosed |
| CN-112334466-B | Compounds of formula (I) | CTXT私人有限公司 | 2025-05-30 | — | — | CN | disclosed |
| EP-4335439-A2 | COMPOUNDS | CTXT PTY LTD (AU) | 2024-03-13 | — | — | EP | disclosed |
| US-11911372-B2 | Compounds | CTXT PTY LTD (AU) | 2024-02-27 | — | — | US | disclosed |
| US-11911372-B2 | Compounds | CTXT PTY LTD (AU) | 2024-02-27 | — | — | US | disclosed |
| EP-3810602-B1 | COMPOUNDS | CTXT PTY LTD (AU) | 2023-11-01 | — | — | EP | disclosed |
| EP-3810602-B1 | COMPOUNDS | CTXT PTY LTD (AU) | 2023-11-01 | — | — | EP | disclosed |
| US-20020156295-A1 | Ligands for metals and improved metal-catalyzed processes based thereon | NATIONAL SCIENCE FOUNDATION | 2002-10-24 | — | — | US | disclosed |
| EP-1216235-A1 | QUINAZOLINONES | MERCK PATENT GmbH (DE) | 2002-06-26 | — | — | EP | disclosed |
| US-6395916-B1 | AMINE, PHOSPHINE LIGANDS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2002-05-28 | — | — | US | disclosed |
| US-6307087-B1 | USE OF CATALYSTS COMPRISING THESE LIGANDS IN TRANSITION METAL-CATALYZED CARBON-HETEROATOM AND CARBON-CARBON BOND-FORMING REACTIONS. | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2001-10-23 | — | — | US | disclosed |
| EP-1097158-A2 | LIGANDS FOR METALS AND METAL-CATALYZED PROCESSES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2001-05-09 | — | — | EP | disclosed |
| WO-2001023365-A1 | QUINAZOLINONES | MERCK PATENT GMBH (DE) | 2001-04-05 | — | — | WO | disclosed |
| WO-2000002887-A2 | LIGANDS FOR METALS AND METAL-CATALYZED PROCESSES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2000-01-20 | — | — | WO | disclosed |
| WO-1996030361-A1 | PROCESS FOR 2-SUBSTITUTED BENZO[b]THIOPHENE COMPOUNDS AND INTERMEDIATES THEREOF | ELI LILLY AND COMPANY (US) | 1996-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075324-A1 | Melanin concentrating hormone antagonists | MCHR1, MCHR2, MC1R | CYP1A1 1346/4885CYP1B1 1061/4885CYP1A2 690/4885 |
| US-20020156295-A1 | Ligands for metals and improved metal-catalyzed processes based thereon | THEM6, SOD1, SLC30A6 | CYP1A1 1333/4885CYP1B1 1849/4885CYP1A2 771/4885 |
| US-11911372-B2 | Compounds | SLC10A1, ABCB11, REN | CYP1A1 189/4885CYP1B1 121/4885CYP1A2 157/4885 |
| US-12365655-B2 | Compounds | SLC10A1, ABCB11, PCSK9 | CYP1A1 128/4885CYP1B1 93/4885CYP1A2 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.